Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 16, Issue 11, Pages 1467-1503Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2010.08.001
Keywords
Allogeneic hematopoietic stem cell transplantation; Treatment; Donor lymphocyte infusion
Categories
Funding
- NCI NIH HHS [K24 CA117879] Funding Source: Medline
Ask authors/readers for more resources
Relapse is a major cause of treatment failure after allogeneic hematopoietic stern cell transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the majority of patients ultimately die of their disease. There is no standard approach to treating relapse after alloHSCT. Withdrawal of immune suppression and donor lymphocyte infusions are commonly used for all diseases; although these interventions are remarkably effective for relapsed chronic myelogenous leukemia, they have limited efficacy in other hematologic malignancies. Conventional and novel chemotherapy, monoclonal antibody therapy, targeted therapies, and second transplants have been utilized in a variety of relapsed diseases, but reports on these therapies are generally anecdotal and retrospective. As such, there is an immediate need for well-designed, disease-specific trials for treatment of relapse after alloHSCT. This report summarizes current treatment options under investigation for relapse after alloHSCT in a disease-specific manner. In addition, recommendations are provided for specific areas of research necessary in the treatment of relapse after alloHSCT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available